Literature DB >> 14739627

Pre-hospital fibrinolysis followed by angioplasty or primary angioplasty in acute myocardial infarction: the long-term clinical outcome.

J Roncalli1, F Brunelle, M Galinier, D Carrié, J Fourcade, M Elbaz, J P Gaston, S Charpentier, J Puel, J M Fauvel.   

Abstract

BACKGROUND: Randomized trials comparing primary angioplasty and in-hospital fibrinolysis in acute myocardial infarction (AMI) have shown an advantage for primary angioplasty. The long-term follow-up of pre-hospital fibrinolysis followed by elective or rescue coronary angioplasty versus primary angioplasty is not well established after acute myocardial infarction. This study sought to assess the long-term clinical outcome of patients with AMI having either received pre-hospital fibrinolysis optimized by coronary angioplasty or primary angioplasty.
METHODS: We conducted a retrospective analysis involving 318 patients who either underwent primary angioplasty ( n = 157) or received pre-hospital fibrinolysis followed by an angioplasty (rescue or elective) ( n = 161) within 6 hours of the onset of chest pain.
RESULTS: The groups were similar regarding their baseline characteristics except for the ages. No difference was noted for in-hospital mortality (primary PTCA group: 2.48%, combined group: 2.54%; p = ns) with no increased risk of hemorrhage. The 3-year mortality was not significantly different in the two groups (9.7% vs. 4.9%; p = 0.15). Regarding major adverse cardiac events (29.5% vs. 37.5%; p = 0.23), reintervention (22.5% vs. 23.2%; p = 0.99) or target lesion revascularization (16.1% vs. 14.7%; p = 0.68), the groups were statistically similar.
CONCLUSION: These data from real-life practice emphasize the safety and similar benefits on the long-term clinical outcome of AMI patients having undergone either pre-hospital fibrinolysis followed by angioplasty or primary angioplasty.

Entities:  

Mesh:

Year:  2003        PMID: 14739627     DOI: 10.1023/B:THRO.0000011373.44451.8b

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  31 in total

1.  Short- and long-term mortality for patients undergoing primary angioplasty for acute myocardial infarction.

Authors:  E L Hannan; M J Racz; D T Arani; T J Ryan; G Walford; B D McCallister
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

2.  Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).

Authors:  A J Tiefenbrunn; N C Chandra; W J French; J M Gore; W J Rogers
Journal:  J Am Coll Cardiol       Date:  1998-05       Impact factor: 24.094

3.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.

Authors:  W D Weaver; R J Simes; A Betriu; C L Grines; F Zijlstra; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; M A DeWood; F Ribichini
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

4.  Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT).

Authors:  J M Rawles
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

5.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

6.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial.

Authors:  W D Weaver; M Cerqueira; A P Hallstrom; P E Litwin; J S Martin; P J Kudenchuk; M Eisenberg
Journal:  JAMA       Date:  1993-09-08       Impact factor: 56.272

7.  A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group.

Authors:  C L Grines; K F Browne; J Marco; D Rothbaum; G W Stone; J O'Keefe; P Overlie; B Donohue; N Chelliah; G C Timmis
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

8.  Applicability of percutaneous transluminal coronary angioplasty to patients with recombinant tissue plasminogen activator mediated thrombolysis.

Authors:  E J Topol; J E Eha; K P Brin; E P Shapiro; J L Weiss; M B Riegel; S O Gottlieb; J A Brinker
Journal:  Cathet Cardiovasc Diagn       Date:  1985

9.  Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival.

Authors:  M L Simoons; P W Serruys; M van den Brand; J Res; F W Verheugt; X H Krauss; W J Remme; F Bär; C de Zwaan; A van der Laarse
Journal:  J Am Coll Cardiol       Date:  1986-04       Impact factor: 24.094

10.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

Authors:  E J Topol; R M Califf; B S George; D J Kereiakes; C W Abbottsmith; R J Candela; K L Lee; B Pitt; R S Stack; W W O'Neill
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.